While the life sciences and health care industry is witnessing a rise of environmental and societal impact, how focused are investors in this regard? At the same time, the role of companies in tackling the pandemic is more important than ever. While technological innovation is constantly disrupting the pharma landscape, how will it reshape manufacturing and supply chains for uninterrupted operations in the new normal? The industry has also been embracing patient-centered approaches in its strive to improve consumer empowerment. But, does patient centricity make strategic sense? Deloitte leaders, along with industry peers, unpacked many of these critical questions at the FT Global Pharmaceutical & Biotechnology Conference 2021, which brought together the biggest life sciences and health care leaders from across the globe virtually to discuss. The leaders navigated the route to deliver better health care outcomes in an uncertain world.
Deloitte was once again the lead sponsor of the 2021 Financial Times Global Pharmaceutical & Biotechnology Conference and was pleased to offer a free complimentary registration to this year’s conference.
- Innovating and collaborating: Assess the legacy of COVID-19 for healthcare and life sciences and the potential impact on how products are developed in the future
- Investing and expanding: Explore the pharma biotech investment landscape and identify opportunities for growth around the world
- Engaging and empowering: Gain global insights on market access and the future of healthcare from different stakeholders including pharma, payers, patients and regulators
Deloitte participation sessions:
*Registration required to access conference recordings. Complimentary registration is available for senior executives in the life sciences and health care industry only and is subject to final approval by the Financial Times Live.